ctapharma USA has received U.S. Food and Drug Administration Emergency Use Authorization (EUA) for its proprietary octaplasLG Powder (blood group types A and AB). 

Octapharma USA Receives FDA Emergency Use Authorization for octaplasLG Powder, Allows U.S. Military Medical Providers Emergent Use in Treatment of Hemorrhage or Coagulopathy

Octapharma USA Receives FDA Emergency Use Authorization for octaplasLG Powder

Octapharma USA announced the results from the Phase III (LEX-209) study on the efficacy and safety of Balfaxar® (prothrombin complex concentrate) have been published by the JAMA Network Open, an American Medical Association peer-reviewed journal.

Octapharma USA: JAMA network open publishes study results demonstrating efficacy & safety of Balfaxar® for warfarin reversal in urgent surgery & invasive procedures

Octapharma USA: JAMA Network Open Publishes Study Results Demonstrating Efficacy & Safety of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures

JAMA publishes study on Balfaxar® efficacy for warfarin reversal in surgery

Octapharma supports the PROXY trial to evaluate if 4F-PCC can prevent excessive bleeding during emergency surgery in patients on FXa inhibitors, without increasing thrombotic risk

Improving care for AF Patients: Managing factor Xa inhibitor bleeding risks in urgent surgery 

Octapharma USA, Inc. has announced the expanded approval of fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for fibrinogen replacement in bleeding patients with acquired fibrinogen deficiency (AFD) by the U.S. Food and Drug Administration (FDA). 

FDA approves fibryga® for acquired fibrinogen deficiency, potentially ushering in a new standard of care

ESAIC 2024 showcased the best of innovations in anaesthesia, intensive care, and emergency medicine to an international audience of over 6,000 healthcare professionals. Octapharma made a significant impact at the event.

Octapharma at ESAIC 2024: Advancing Surgical Bleeding and Coagulation Management 

The most recent developments from Octapharma’s Haematology portfolio will be presented at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) on June 22–26, 2024, in Bangkok, Thailand. 

Octapharma’s continuing dedication to improving the lives of people with rare bleeding disorders to be showcased at ISTH 2024

Octapharma presented exciting new data and core initiatives to leading experts and opinion leaders at the World Federation of Hemophilia (WFH) 2024 World Congress in Madrid, Spain..

Octapharma at the forefront of rare bleeding disorders at the WFH 2024 World Congress

Octapharma at the forefront of rare bleeding disorders at the WFH 2024 World Congress in Madrid, Spain

The American Academy of Neurology (AAN) Annual Meeting, held from April 13-18, 2024, in Denver, Colorado, marked a significant event in the world of neurology. 

Octapharma makes a strong impression at the 2024 AAN Annual Meeting in Denver

Octapharma Dessau is dedicated to upholding high standards in both business and employee experience. Recently, it was  honored as a regional finalist for the national “Großer Preis des Mittelstands” (the “Grand Prize for Small and Medium-Sized Businesses”).

Octapharma Dessau shines as a regional finalist in the prestigious “Großer Preis des Mittelstands”

Octapharma USA, Inc. announced the FDA has granted orphan drug exclusivity for wilate® for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children 6 years of age and older with von Willebrand disease (VWD).

Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®, the First VWF Concentrate for Prophylaxis in All Types of VWD

World Myositis Day, recognised annually on September 21, aims to raise awareness of a group of rare, autoimmune diseases, collectively referred to as myositis. 

Raising awareness of myositis 

Visit VWDtest.com

Launch of the improved vwdtest.com website is a central component of a global initiative aimed at increasing awareness of von Willebrand disease (VWD).

Expanded website will raise awareness of von Willebrand disease

The VWDtest.com website has been updated and expanded. 

Creating a positive impact is what Octapharma is all about

Claremont Moyo, Divisional Director of Operations, Octapharma Plasma, Inc., Charlotte, North Carolina, USA

Amanda Keller, Manager of Automated Systems Support, Genesys team, Virginia Beach, Virginia, USA

Patrick McFall, Human Resources Recruiter, Corporate Office, Charlotte, North Carolina, USA

Anna Rowe, Senior Automated Systems Analyst, Genesys team, Omaha, Nebraska, USA

Joel Arnold, Regional Director of Operations, Nashville, Tennessee, USA

Reaching new donors

Creating a positive impact is what Octapharma is all about.

Annual Report 2019

A group of Indonesian doctors seized a unique opportunity to visit Octapharma’s cutting-edge production site in Springe, Germany. This exclusive tour provided them with a comprehensive understanding of the sophisticated processes involved in manufacturing high-quality medical products.

Indonesian doctors gain unique insights at Octapharma Springe

New clinical and scientific findings advance our understanding and treatment of bleeding disorders. The congress takes place in Frankfurt, Germany from February 6-9, 2024-

Octapharma to present clinical and scientific data at EAHAD 2024

Octapharma to present clinical and scientific data at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders

World Blood Donor Day: celebrating every donation

Elodie Neuner works at the Octapharma production site in Lingolsheim, France

Imke Franzaring, Marketing Manager at Octapharma Plasma Germany

June 14 is World Blood Donor Day, an opportunity to celebrate the people who give their blood to help patients in need and to raise aware of the tremendous importance of every donation.

Industry recognition: a testament to excellence

Special projects team: Innovating together

In 2003, Octapharma obtained approval from the US FDA for intravenous human normal immunoglobulin (IVIg) to treat PID in the USA and began to explore growing its presence in the world’s largest market.

Octapharma USA: Two decades of pioneering patient-centred care

Two decades of pioneering patient-centred care

Octapharma is Committed to Supplying Hospitals and Medical Providers with New Prothrombin Complex Concentrate..

Octapharma Announces Availability of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures

Entrepreneurship

We asked five colleagues from around the globe what the Octapharma values mean to them – and their answers reveal some very personal and motivating responses.

Entrepreneurship is the pursuit of opportunities

Octapharma announced today the publication of the results from the clinical study WIL-31, which investigated the efficacy and safety of prophylaxis with wilate®, a von Willebrand factor/factor VIII (VWF/FVIII) concentrate, in patients with all types of von Willebrand disease (VWD).

Publication of data from WIL-31 study marks a milestone in improving long-term care for patients with severe von Willebrand disease (VWD)

Sustainability

We asked five colleagues from around the globe what the Octapharma values mean to them – and their answers reveal some very personal and motivating responses. 

Sustainability is essential to create an inclusive work environment

Sustainability  is essential to create an inclusive work environment

Routine Prophylaxis Now Recommended for Adults and Children Aged 6 and Older with Severe VWD

Octapharma USA: FDA Grants Expanded Approval to wilate® as the First VWF Concentrate for Prophylaxis in All Types of VWD

Octapharma announces that the final results from the phase III ProDERM study will be presented at the American College of Rheumatology (ACR) Convergence 2020 virtual meeting. The ProDERM study assessed the long-term efficacy, tolerability and safety of octagam® 10%, an intravenous immunoglobulin (IVIg)

Positive results from ProDERM study of octagam® 10% 

Positive results from ProDERM study of octagam® 10% in patients with dermatomyositis meeting the primary endpoint will be presented at ACR Convergence 2020

Leadership

 Leadership means standing up to remove roadblocks 

Thanks to the efforts of our Octapharma Plasma USA and Global IT teams, all our plasma donation centers in the USA have been fully operational again since April 25. Our production sites were not impacted by this event, and we have been able to maintain our normal production schedules of our life-saving therapies.

News Update

New data from ongoing research initiatives aimed at advancing care for people living with bleeding disorders will be presented during the scientific program at the 65th American Society of Hematology (ASH) Meeting and Exposition on December 9-12, 2023.

Octapharma to present new clinical and scientific data at ASH 2023

Octapharma to present new clinical and scientific data at ASH 2023 from ongoing research initiatives aimed at advancing care for people living with bleeding disorders

Marcus Wahlqvist, Head of the Logistics Centre in Arlandastad.

Single Donation Control – an important step in Octapharma’s quality chain.

Kristoffer Ghazal, a SDC operator, distributes frozen plasma to the lines for visual and computerised checks.

Organising operations at the Logistics Centre is a complex matter.

An operator weighs material for production

Seven days a week, the logistics centre receives incoming materials, both raw materials and plasma, which are then sent off and used in production at the Octapharma's Stockholm site.

It all starts at Octapharma Logistics Centre in Arlandastad, Sweden!

It all starts at Octapharma Logistics Centre in Arlandastad, Sweden

It all starts at Octapharma AB’s Logistics Centre in Arlandastad

Octapharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved an updated Prescribing Information (PI) for NUWIQ®, Octapharma’s human cell line-derived recombinant factor VIII (FVIII). NUWIQ ® is approved for the prevention and treatment of bleeding in people with haemophilia A. 

Octapharma announces FDA approval of updated NUWIQ® Prescribing Information to include immunogenicity data in previously untreated patients

Integrity

Integrity is integrated into our governance

International Women's Day is a global celebration honouring the achievements of women in various spheres of life. To celebrate International Women's Day this year, we interviewed a few women accross Octapharma.

Celebrating International Women's Day

Celebrating International Women's Day  

Indirect comparison data indicate that personalised prophylaxis with Nuwiq® may lead to fewer patients with haemophilia A having bleeds than with other recombinant factor VIII products.

New Nuwiq® study published in the European Journal of Haematology

Did you know?

This September, the Platelet Disorder Support Association (PDSA) is raising awareness of immune thrombocytopenic purpura (ITP), a rare autoimmune disorder characterised by a decrease in the number of platelets in the blood that can result in bruising, bleeding gums and internal bleeding.

Raising awareness of immune thrombocytopenic purpura

Octagam®10% expected to become the first treatment option for adults with rare immune-mediated inflammatory disease

FDA Orphan Drug approval: Octapharma’s Octagam® 10% receives 7 years of market exclusivity for adult dermatomyositis

Octapharma’s Octagam® 10% Receives 7 Years of Market Exclusivity for Adult Dermatomyositis

Patient recruitment starts for the international PRO-SID study evaluating Panzyga for primary prophylaxis in patients with chronic lymphocytic leukaemia and secondary immunodeficiency

Patient recruitment starts for the international PRO-SID study evaluating Panzyga® for primary prophylaxis in patients with chronic lymphocytic leukaemia and secondary immunodeficiency

Ownership

Jorge Fernández, Deputy General Manager Octapharma Mexico City, Mexico

Ownership means making sure that each of our actions brings a positive outcome to our patients

Octapharma USA will be presented with the Research & Development Award for Outstanding Innovation in Myositis Research during the Heroes in the Fight Awards Celebration at The Myositis Association’s 2023 International Annual Patient Conference to be held September 7 - 10 in San Diego.

Heroes in the Fight: Octapharma To Be Honored for Myositis Research at TMA Annual Patient Conference

Andrea Heger, Team Leader for Plasma R&D, Octapharma Vienna

Elisabeth Tomaz, Qualified Person, Batch Assessment & Administration of Complaints, Octapharma Vienna

Fany Chauvel, Corporate Head of People, Organisation and Culture, Octapharma

International Women's Day (March 8) is a global celebration of the social, economic, cultural, and political achievements of women.

Dina Dickson CRM Project Manager, Octapharma USA

Thomas Stork Sales Manager, Octapharma Germany

Michele Noll Research Associate Quality Control/ Qualified Person, Octapharma Biopharmaceuticals, Germany

Alma Torokoff Pharmaceutical Technician, Biopharmaceutical Production, Octapharma Sweden

Andra Jones Senior Director, Operations, Octapharma Plasma, Inc.

At Octapharma, we foster a culture that brings out the best in our people to fulfil our purpose of providing new health solutions advancing human life. We believe we can drive innovation, performance and reputation – and enhance our people’s work experience – through our culture. 

Building on strong values 

Annual Report 2021

Building on strong values

The U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease.

FDA Approves Octapharma’s Octagam® 10%  for Adult Dermatomyositis

Louis DiCriscio, Senior Vice President, Finance & Operations, Octapharma USA, Inc.

Snehal Udavat, Study Manager, Immunology & ICE, Octapharma USA, Inc.

Huub Kreuwel, Vice President, Scientific & Medical Affairs, Octapharma USA, Inc.

Andrea Buchacher, Head of Quality Unit, Octapharma Austria 

Clare Worden, General Manager, Octapharma UK

Beyond our core values – ownership, integrity, leadership, sustainability and entrepreneurship – we aspire to create a culture in which our employees feel inspired. Here are five snapshots of how our culture is taking shape.

Culture drives performance

Annual Report 2020

Octapharma USA Announces Medicare Part B Approval of cutaquig® 16.5% for Adult PI Patients

Our values 

Our shared company values

The Octapharma Group once again delivered impressive growth in 2023, with sales up 14.4% over the prior year to a new record of €3.266 billion. This growth was driven by a substantial increase in plasma collection and continuing strong demand for our products.

Delivering strong performance in 2023

Financial review

Financial review 2023

Octapharma's prothrombin complex concentrate, Balfaxar®, receives FDA approval for warfarin reversal in urgent surgery & invasive procedures

Octapharma's Prothrombin Complex Concentrate, Balfaxar®, Receives FDA Approval For Warfarin Reversal in Urgent Surgery & Invasive Procedures

Manage Dermatomyositis Information Hub

To mark Rare Disease Day on February 28, we take an in-depth look at one such disease which Octapharma has had an important impact on as part of its commitment to helping patients around the world who are suffering with rare diseases: dermatomyositis.

Rare Disease Day: A look at dermatomyositis

Octapharma announced today that new clinical and scientific findings encompassing their Haematology portfolio, including Nuwiq®, wilate®, octanate® and octanine®F, will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place on July 17–21, 2021. 

Octapharma’s ongoing dedication to be showcased at the ISTH 2021 Congress

Octapharma’s ongoing dedication to improving the lives of people with haemophilia and von Willebrand disease to be showcased at the ISTH 2021 Congress

ISTH 2021 new clinical and scientific findings encompassing the Haematology portfolio

Octapharma Launches Phase 3 Superiority Study for Pediatric Acute-onset Neuropsychiatric Syndrome

Octapharma has launched a phase 3, multicenter superiority study to compare the effectiveness of PANZYGA® (immune globulin intravenous, human - ifas) 10% Liquid Preparation versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome (PANS).

Multicenter Clinical Trial to Compare the Effectiveness of PANZYGA® Versus Placebo in Children and Adolescents from age 6 to 17

New IgCares app helps patients safely manage PI

Octapharma USA has launched the IgCares mobile app, an innovative e-health solution, as part of a program that helps patients and their caregivers safely manage primary immunodeficiency (PI).

New ‘IgCares’ app helps patients safely manage PI

From left to right: Carole Michelson; Jonathan Prater; Alice Stewart; Bill Griner.

A positive impact

Plasma collection is the foundation for our work. In 2019, we expanded our network of plasma donation centres to reach a growing number of donors. 

In 2023, Octapharma celebrated 40 years of innovation and success since our company was founded in 1983 by two men with a shared vision to provide haemophilia patients with a safe and efficacious factor VIII (FVIII) replacement therapy. It was also a year of extraordinary achievement.

Building on our successes - Letter from our CEO

Letter from our CEO

Building on our successes

Reaching new hights in plasma collection

In 2010, Karin began donating plasma regularly at Octapharma Plasma. While helping others is a big motivator for Karin, it is the people at her donation centre who keep her coming back to Octapharma Plasma.

Loyalty and community

Donor story

The data will be featured in nine poster presentations and two Supported Symposia during this key international meeting. 

Octapharma presents new data at ISTH 2023 in an ongoing commitment to improve the lives of people with bleeding disorders

Annual Report 2022

The Octapharma Group once again delivered strong results in a challenging environment in 2022, with record sales, operating profit, profit before tax and net profit. 

Octapharma Group delivers strong growth in sales and operating income in 2022

Octapharma demonstrates its continued mission to meet the challenges faced by people with bleeding disorders.

Octapharma to present new clinical data and studies at ASH 2022

Octapharma to present new clinical data and studies at ASH 2022 to demonstrate its continued mission to meet the challenges faced by people with bleeding disorders

Octapharma announced today that octagam® 10%, a human plasma-derived intravenous immunoglobulin (IVIg), has recently been granted approval in the European Union (EU) as an immunomodulatory therapy for adults with dermatomyositis. Following the EU approval, octagam 10%® received national approval in Germany on May 11, 2

European and German authorities approve octagam® 10% for adults with dermatomyositis 

Approval of octagam 10% for adults with dermatomyositis 

Octapharma’s Fibryga® receives Health Canada approval to treat acquired fibrinogen deficiency (AFD) in surgical settings

Octapharma Canada announces that Fibryga® (Human Fibrinogen Concentrate, HFC) has received Health Canada approval for use in treatment of acquired fibrinogen deficiency (AFD), in the course of surgical interventions.

 Octapharma Italy launches WiCare, home care for patients with von Willebrand disease

Octapharma Italy has partnered with Domedica, a company with experience in integrated healthcare, to develop the WiCare program to provide home support to patients suffering from von Willebrand disease (vWD) including many who have difficulty accessing healthcare due to the COVID-19 pandemic.

Octapharma Italy launches WiCare, home care for patients with von Willebrand disease

Petra Löfgren,  Shift Manager

Twenty years and still enjoying the challenge...

"We are Octapharma" film series

Reaching new heights in plasma collection

Plasma-derived therapies are lifesaving, but they rely on donations. Mike started donating at Octapharma Plasma more than a decade ago and is committed to donating twice a week. 

Donor story: Just an ordinary lifesaver

Just an ordinary lifesaver

Real-world data and expert perspectives on state-of-the-art clinical practice for the management of infection in patients with CLL will be showcased during the Octapharma Update-in-Hematology session at the EHA Hybrid Congress on June 9, 2023, in Frankfurt, Germany. 

Octapharma puts a spotlight on the infection burden in patients with Chronic Lymphocytic Leukaemia (CLL) at the European Hematology Association (EHA) Hybrid Congress 2023 

Octapharma puts a spotlight on the infection burden in patients with CLL at the EHA Congress 2023 

Delivering strong results in 2022

Delivering strong performance in 2022

ProDERM study results of octagam® 10% treatment in patients with dermatomyositis published in the New England Journal of Medicine. 

ProDERM study results of octagam® 10% treatment in patients with dermatomyositis published in the New England Journal of Medicine

Thoralf Petzold, General Manager for Octapharma Dessau

Octapharma Dessau is working with local authorities in the German city to help provide furnished accommodation to refugees escaping the war in Ukraine.

News

About us

Plasma

Products

Careers

Engagement

News